Y-Mabs Therapeutics
Y-mAbs is a biopharmaceutical company developing and commercializing novel radioimmunotherapy and antibody-based therapies, now part of SERB Pharmaceuticals.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Y-mAbs Therapeutics is a biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapies for challenging diseases. Founded in 2015 by Thomas Gad, the company is now part of SERB Pharmaceuticals. Its first commercial product is DANYELZA® (naxitamab-gqgk).
History
Y-mAbs was founded in 2015 by Thomas Gad, who launched the company to help families access cutting-edge therapies like those used to treat his daughter with high-risk neuroblastoma. The company is now part of SERB Pharmaceuticals.
Products and positioning
DANYELZA®
First commercial product, naxitamab-gqgk, with boxed warning on serious infusion-related reactions and neurotoxicity.
Recent events
Y-mAbs prices public stock offering[5]
Y-mAbs Therapeutics announced pricing for a public offering of 2,439,025 common shares at $41.00 per share, with gross proceeds expected to be approximately $100 million. The offering was expected to close on February 22, subject to customary conditions.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/y-mabs-therapeutics · Editorial policy · How profiles are compiled